Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 13/20 | 0.87 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.87 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.71 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.71 |
| ▸ | VDR | P11473 | 1/20 | 0.71 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392478 | 1.00 | GRIN1 (0.87) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL15994082 | 1.00 | GRIN1 (0.87) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL15796049 | 1.00 | GRIN1 (0.87) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL19253197 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL14941191 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL14941193 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL14941061 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL15921398 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL7011421 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A | |
| SCHEMBL15921397 | 0.89 | GRIN1 (0.83) | GRIN1GRIN2BABCC4GRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20190091149-A1 | Oil foamable carriers and formulations | FOAMIX PHARMACEUTICALS LTD. | 2019-03-28 | — | — | US | disclosed |
| US-20170348418-A1 | Foamable Vehicle and Pharmaceutical Compositions Thereof | FOAMIX PHARMACEUTICALS, LTD. (IL) | 2017-12-07 | — | — | US | disclosed |
| US-20170181970-A1 | Oil foamable carriers and formulations | FOAMIX LTD. (IL) | 2017-06-29 | — | — | US | disclosed |
| US-9636405-B2 | Foamable vehicle and pharmaceutical compositions thereof | FOAMIX PHARMACEUTICALS LTD. (IL) | 2017-05-02 | — | — | US | disclosed |
| US-9549898-B2 | Oil and liquid silicone foamable carriers and formulations | FOAMIX PHARMACEUTICALS LTD. (IL) | 2017-01-24 | — | — | US | disclosed |
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-20150118164-A1 | Oil and Liquid Silicone Foamable Carriers and Formulations | SWK FUNDING LLC | 2015-04-30 | — | — | US | disclosed |
| US-8961586-B2 | Bifurcated stent assemblies | INSPIREMD LTD. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8900553-B2 | Oil and liquid silicone foamable carriers and formulations | FOAMIX PHARMACEUTICALS LTD. (IL) | 2014-12-02 | — | — | US | disclosed |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2008-03-20 | — | — | US | disclosed |
| EP-1893396-A2 | FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | Foamix Ltd. (IL) | 2008-03-05 | — | — | EP | disclosed |
| US-20070276468-A1 | Bifurcated stent assemblies | INSPIREMD LTD. (IL) | 2007-11-29 | — | — | US | disclosed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007054818-A2 | FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX LTD. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060275218-A1 | Foamable vehicle and pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2006-12-07 | — | — | US | disclosed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060034779-A1 | Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same | AGIS INDUSTRIES (1983) LTD. (IL) | 2006-02-16 | — | — | US | disclosed |
| US-20060024243-A1 | Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same | AGIS INDUSTRIES (1983) LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091149-A1 | Oil foamable carriers and formulations | LIPA, PTGER1, TTPA | GRIN1 2894/4885GRIN2B 3514/4885ABCC4 1458/4885 |
| US-20150118164-A1 | Oil and Liquid Silicone Foamable Carriers and Formulations | LIPA, LPXN, PTGER1 | GRIN1 3155/4885GRIN2B 3629/4885ABCC4 1995/4885 |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | PROC, VKORC1, TTPA | GRIN1 4879/4885GRIN2B 4885/4885ABCC4 370/4885 |
| US-20170181970-A1 | Oil foamable carriers and formulations | LIPA, PTGER1, TTPA | GRIN1 2894/4885GRIN2B 3514/4885ABCC4 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.